Fineline Cube

Follow:
14435 Articles
Dizal Pharma's DZD8586 Granted FDA Fast Track Designation for CLL/SLL Treatment
CompanyDrug

Dizal Pharma’s DZD8586 Granted FDA Fast Track Designation for CLL/SLL Treatment

AstraZeneca's Fasenra Approved for Pediatric Severe Eosinophilic Asthma in China
CompanyDrug

AstraZeneca’s Fasenra Approved for Pediatric Severe Eosinophilic Asthma in China

Sino Biopharmaceutical's Rovadicitinib Granted Breakthrough Therapy Designation for Chronic Graft-versus-Host Disease
CompanyDrug

Sino Biopharmaceutical’s Rovadicitinib Granted Breakthrough Therapy Designation for Chronic Graft-versus-Host Disease

Guangzhou Innogen Pharmaceuticals Launches H-Share Global Offering in Hong Kong
CompanyDeals

Guangzhou Innogen Pharmaceuticals Launches H-Share Global Offering in Hong Kong

BeOne Medicines Reports 42% Revenue Growth in Q2 2025 Driven by Brukinsa Sales
Company

BeOne Medicines Reports 42% Revenue Growth in Q2 2025 Driven by Brukinsa Sales

Sino Medical Sciences' COMETIU Stent System and COMEX Catheter Receive FDA Breakthrough Designation
CompanyMedical Device

Sino Medical Sciences’ COMETIU Stent System and COMEX Catheter Receive FDA Breakthrough Designation

Novartis Evaluates Acquisition of Avidity Biosciences to Strengthen Rare Disease Pipeline
CompanyDeals

Novartis Evaluates Acquisition of Avidity Biosciences to Strengthen Rare Disease Pipeline

Shanghai Issues New Measures to Boost Commercial Health Insurance for Biopharmaceutical Innovation
Policy / Regulatory

Shanghai Issues New Measures to Boost Commercial Health Insurance for Biopharmaceutical Innovation

Hengrui's Trastuzumab Rezetecan Granted FDA Orphan Drug Designation for Gastric Cancer Treatment
CompanyDrug

Hengrui’s Trastuzumab Rezetecan Granted FDA Orphan Drug Designation for Gastric Cancer Treatment

Pfizer's Q2 2025 Revenue Rises 10% Driven by Strong Biopharma Sales
Company

Pfizer’s Q2 2025 Revenue Rises 10% Driven by Strong Biopharma Sales

Novo Nordisk Reports Strong H1 2025 Financial Results Driven by Semaglutide Sales
Company

Novo Nordisk Reports Strong H1 2025 Financial Results Driven by Semaglutide Sales

Qyuns Therapeutics' QX004N Enters Phase 3 Trials for Psoriasis and Crohn’s Disease
CompanyDrug

Qyuns Therapeutics’ QX004N Enters Phase 3 Trials for Psoriasis and Crohn’s Disease